Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs). The proposed research should develop, and/or adapt, revolutionary techniques or methods for addiction research or that show promising future applicability to SUD research, and/or test an innovative and significant hypothesis for which there are scant precedent or preliminary data and which, if confirmed, would transform current thinking. Key aspects of this opportunity include: • Support for high-risk and potentially high-impact research that is underrepresented or not included in NIDA's current portfolio • Emphasis on transforming SUD research through innovative techniques, methods, or hypotheses • Eligibility for various types of organizations, including state and local governments, nonprofits, and for-profit businesses • Availability of funding for up to 2 years, with an estimated total award amount of $150,000